The DOI matches its Crossref record; 70 of the 70 references it cites were found in a registry or an index.
Dysbindin-1 is reduced in intrinsic, glutamatergic terminals of the hippocampal formation in schizophrenia
Open accessAbstract
Eleven studies now report significant associations between schizophrenia and certain haplotypes of singlenucleotide polymorphisms in the gene encoding dysbindin-1 at 6p22.3.Dysbindin-1 is best known as dystrobrevin-binding protein 1 (DTNBP1) and may thus be associated with the dystrophin glycoprotein complex found at certain postsynaptic sites in the brain.Contrary to expectations, however, we found that when compared to matched, nonpsychiatric controls, 73-93% of cases in two schizophrenia populations displayed presynaptic dysbindin-1 reductions averaging 18-42% (P = 0.027-0.0001)at hippocampal formation sites lacking neuronal dystrobrevin (i.e., β-dystrobrevin).The reductions, which were not observed in the anterior cingulate of the same schizophrenia cases, occurred specifically in terminal fields of intrinsic, glutamatergic afferents of the subiculum, the hippocampus proper, and especially the inner molecular layer of the dentate gyrus (DGiml).An inversely correlated increase in vesicular glutamate transporter-1 (VGluT-1) occurred in DGiml of the same schizophrenia cases.Those changes occurred without evidence of axon terminal loss or neuroleptic effects on dysbindin-1 or VGluT-1.Our findings indicate that presynaptic dysbindin-1 reductions independent of the dystrophin glycoprotein complex are frequent in schizophrenia and are related to glutamatergic alterations in intrinsic hippocampal formation connections.Such changes may contribute to the cognitive deficits common in schizophrenia.Nonstandard abbreviations used: cornu ammonis fields 1-3 of the hippocampus (CA1-3); dentate gyrus (DG); DG granule cell layer (DGg); DG hilus (DGh); DG inner molecular layer (DGiml); diaminobenzidine (DAB); hippocampal formation (i.e., CA1-3 + DG + subiculum) (HF); neuronal nucleus antibody (NeuN); postmortem interval (PMI); single-nucleotide polymorphism (SNP); vesicular glutamate transporter-1 (VGluT-1).Conflict of interest:The authors have declared that no conflict of interest exists.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Paxinos, G. (1985) · Cited by 3,715
Paxinos, G., & Jürgen, K. (2004) · Cited by 1,478
Function and Genetics of Dystrophin and Dystrophin-Related Proteins in Muscle
Blake, D. J., Weir, A., Newey, S. E., & Davies, K. E. (2002) · Physiological Reviews · doi:10.1152/physrev.00028.2001 · Cited by 1,242
Self-citationGenome Scan Meta-Analysis of Schizophrenia and Bipolar Disorder, Part II: Schizophrenia
Lewis, C. M., Levinson, D. F., Wise, L. H., DeLisi, L. E., Straub, R. E., Hovatta, I., Williams, N. M., Schwab, S. G., Pulver, A. E., Faraone, S. V., et al. (2003) · The American Journal of Human Genetics · doi:10.1086/376549 · Cited by 1,137
Requirement for Hippocampal CA3 NMDA Receptors in Associative Memory Recall
Nakazawa, K., Quirk, M. C., Chitwood, R. A., Watanabe, M., Yeckel, M. F., Sun, L. D., Kato, A., Carr, C. A., Johnston, D., Wilson, M. A., et al. (2002) · Science · doi:10.1126/science.1071795 · Cited by 1,099
Organization of intrahippocampal projections originating from CA3 pyramidal cells in the rat
Ishizuka, N., Weber, J., & Amaral, D. G. (1990) · Journal of Comparative Neurology · doi:10.1002/cne.902950407 · Cited by 886
Straub, R. E., Jiang, Y., MacLean, C. J., Ma, Y., Webb, B. T., Myakishev, M. V., Harris-Kerr, C., Wormley, B., Sadek, H., Kadambi, B., et al. (2002) · The American Journal of Human Genetics · doi:10.1086/341750 · Cited by 856
Brodie, S. E. (1996) · Survey of Ophthalmology · doi:10.1016/s0039-6257(96)80075-0 · Cited by 745
Relating Hippocampal Circuitry to Function
Lisman, J. E. (1999) · Neuron · doi:10.1016/s0896-6273(00)81085-5 · Cited by 607
Genes for schizophrenia? Recent findings and their pathophysiological implications
Harrison, P. J., & Owen, M. J. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12379-3 · Cited by 597
Research works printed but not linked: 6
- Bakker, 2003, Am. J. Med. Genet., 122B, 19
- Shi, 2003, Am. J. Med. Genet., 122B, 102
- Yamada, 2003, Am. J. Med. Genet., 122B, 131
- Maier, 2003, Pharmacopsychiatry., 36(Suppl. 3), 5195
- Straub, 2004, Biol. Psychiatry., 55(Suppl. 1), 116S
- Scharfman, 2000, Ann. N. Y. Acad. Sci., 911, ix, 10.1111/j.1749-6632.2000.tb06715.x · doi:10.1111/j.1749-6632.2000.tb06715.x
Cited by
Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence
Harrison, P. J., & Weinberger, D. R. (2005) · Molecular Psychiatry · doi:10.1038/sj.mp.4001558 · Cited by 2,020
Talbot, K., Wang, H.-Y., Kazi, H., Han, L.-Y., Bakshi, K. P., Stucky, A., Fuino, R. L., Kawaguchi, K. R., Samoyedny, A. J., Wilson, R. S., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59903 · Cited by 1,871
Self-citationInterneuron dysfunction in psychiatric disorders
Marín, O. (2012) · Nature Reviews Neuroscience · doi:10.1038/nrn3155 · Cited by 1,190
Lisman, J. E., Coyle, J. T., Green, R. W., Javitt, D. C., Benes, F. M., Heckers, S., & Grace, A. A. (2008) · Trends in Neurosciences · doi:10.1016/j.tins.2008.02.005 · Cited by 1,010
“The expression of dysbindin is reduced in prefrontal cortex and hippocampus in schizophrenia [147].”
BackgroundGlutamate and Schizophrenia: Beyond the Dopamine Hypothesis
Coyle, J. T. (2006) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-006-9062-8 · Cited by 917
“The expression of dysbindin is reduced in prefrontal cortex and hippocampus in schizophrenia (Talbot et al., 2004; Weickert et al., 2004).”
BackgroundBomfim, T. R., Forny-Germano, L., Sathler, L. B., Brito-Moreira, J., Houzel, J.-C., Decker, H., Silverman, M. A., Kazi, H., Melo, H. M., McClean, P. L., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci57256 · Cited by 832
Self-citationRoss, C. A., Margolis, R. L., Reading, S. A. J., Pletnikov, M., & Coyle, J. T. (2006) · Neuron · doi:10.1016/j.neuron.2006.09.015 · Cited by 686
The genetics of schizophrenia and bipolar disorder: dissecting psychosis
Craddock, N., O’Donovan, M. C., & Owen, M. J. (2005) · Journal of Medical Genetics · doi:10.1136/jmg.2005.030718 · Cited by 574
Gao, R., & Penzes, P. (2015) · Current Molecular Medicine · doi:10.2174/1566524015666150303003028 · Cited by 516
“Dysbindin is involved with intracellular trafficking and is downregulated in the prefrontal cortex and hippocampus of SCZ patients [132, 133].”
BackgroundGABAergic Interneurons Shape the Functional Maturation of the Cortex
Le Magueresse, C., & Monyer, H. (2013) · Neuron · doi:10.1016/j.neuron.2013.01.011 · Cited by 425
Endophenotypes in the Genetic Analyses of Mental Disorders
Cannon, T. D., & Keller, M. C. (2006) · Annual Review of Clinical Psychology · doi:10.1146/annurev.clinpsy.2.022305.095232 · Cited by 399
Ayalew, M., Le-Niculescu, H., Levey, D. F., Jain, N., Changala, B., Patel, S. D., Winiger, E., Breier, A., Shekhar, A., Amdur, R., et al. (2012) · Molecular Psychiatry · doi:10.1038/mp.2012.37 · Cited by 397
Glutamate hypothesis in schizophrenia
Uno, Y., & Coyle, J. T. (2019) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12823 · Cited by 367
Evidence of novel neuronal functions of dysbindin, a susceptibility gene for schizophrenia
Numakawa, T., Yagasaki, Y., Ishimoto, T., Okada, T., Suzuki, T., Iwata, N., Ozaki, N., Taguchi, T., Tatsumi, M., Kamijima, K., et al. (2004) · Human Molecular Genetics · doi:10.1093/hmg/ddh280 · Cited by 349
Psychosis pathways converge via D2High dopamine receptors
Seeman, P., Schwarz, J., Chen, J.-F., Szechtman, H., Perreault, M., McKnight, G. S., Roder, J. C., Quirion, R., Boksa, P., Srivastava, L. K., et al. (2006) · Synapse · doi:10.1002/syn.20303 · Cited by 330
Owen, M. J., Craddock, N., & O'Donovan, M. C. (2005) · Trends in Genetics · doi:10.1016/j.tig.2005.06.011 · Cited by 307
The glutamate hypothesis of schizophrenia: evidence from human brain tissue studies
Hu, W., MacDonald, M. L., Elswick, D. E., & Sweet, R. A. (2015) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12547 · Cited by 286
Reviewing the ketamine model for schizophrenia
Frohlich, J., & Van Horn, J. D. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881113512909 · Cited by 303
Osimo, E. F., Beck, K., Reis Marques, T., & Howes, O. D. (2019) · Molecular Psychiatry · doi:10.1038/s41380-018-0041-5 · Cited by 268
Cortical interneuron development: a tale of time and space
Hu, J. S., Vogt, D., Sandberg, M., & Rubenstein, J. L. (2017) · Development · doi:10.1242/dev.132852 · Cited by 189
Molecular genetic studies of schizophrenia
Riley, B., & Kendler, K. S. (2006) · European Journal of Human Genetics · doi:10.1038/sj.ejhg.5201571 · Cited by 190
A Review of Disrupted-in-Schizophrenia-1 (disc1): Neurodevelopment, Cognition, and Mental Conditions
Ishizuka, K., Paek, M., Kamiya, A., & Sawa, A. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.03.065 · Cited by 190
Glutamatergic Synaptic Dysregulation in Schizophrenia: Therapeutic Implications
Coyle, J. T., Basu, A., Benneyworth, M., Balu, D., & Konopaske, G. (2012) · Handbook of Experimental Pharmacology · doi:10.1007/978-3-642-25758-2_10 · Cited by 180
Takao, K., Kobayashi, K., Hagihara, H., Ohira, K., Shoji, H., Hattori, S., Koshimizu, H., Umemori, J., Toyama, K., Nakamura, H. K., et al. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.38 · Cited by 173
Soetanto, A., Wilson, R. S., Talbot, K., Un, A., Schneider, J. A., Sobiesk, M., Kelly, J., Leurgans, S., Bennett, D. A., & Arnold, S. E. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.48 · Cited by 148
Self-citationThe role of cortical inhibition in the pathophysiology and treatment of schizophrenia
Daskalakis, Z. J., Fitzgerald, P. B., & Christensen, B. K. (2007) · Brain Research Reviews · doi:10.1016/j.brainresrev.2007.09.006 · Cited by 111
Carlson, G. C., Talbot, K., Halene, T. B., Gandal, M. J., Kazi, H. A., Schlosser, L., Phung, Q. H., Gur, R. E., Arnold, S. E., & Siegel, S. J. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1109625108 · Cited by 103
Self-citationDysbindin-1, WAVE2 and Abi-1 form a complex that regulates dendritic spine formation
Ito, H., Morishita, R., Shinoda, T., Iwamoto, I., Sudo, K., Okamoto, K., & Nagata, K. (2010) · Molecular Psychiatry · doi:10.1038/mp.2010.69 · Cited by 88
Gokhale, A., Larimore, J., Werner, E., So, L., Moreno-De-Luca, A., Lese-Martin, C., Lupashin, V. V., Smith, Y., & Faundez, V. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.5640-11.2012 · Cited by 85
Fung, S. J., Sivagnanasundaram, S., & Weickert, C. S. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.09.036 · Cited by 54
“We sought to replicate the reduction in dysbindin mRNA expression in the DLPFC (20,43), and to determine if dysbindin mRNA levels may relate to dysbindin genotypes (20,44) and/or may correlate with synaptic pathology as has been previously found in the hippocampus (43,45).”
BackgroundMethodNeuropathology of Schizophrenia
Harrison, P. J., Lewis, D. A., & Kleinman, J. E. (2010) · Schizophrenia · doi:10.1002/9781444327298.ch18 · Cited by 26
EHD1 is a synaptic protein that modulates exocytosis through binding to snapin
Wei, S., Xu, Y., Shi, H., Wong, S.-H., Han, W., Talbot, K., Hong, W., & Ong, W.-Y. (2010) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2010.07.014 · Cited by 22
Self-citation
Metadata
- Authors
- Talbot, K., Eidem, W. L., Tinsley, C. L., Benson, M. A., Thompson, E. W., Smith, R. J., Hahn, C.-G., Siegel, S. J., Trojanowski, J. Q., Gur, R. E., Blake, D. J., & Arnold, S. E.
- Venue
- Journal of Clinical Investigation
- Published
- 2004-05-01
- Volume
- 113
- Issue
- 9
- Pages
- 1353-1363
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2156420407
- Cited by
- 455
- References
- 70
- FWCI
- 23.16
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.